Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …

Background Pathogenic variants of the DPYD gene are strongly associated with grade≥ 3
toxicity during fluoropyrimidine chemotherapy. We conducted a systematic review and meta …

Carriers of the genetic DPYD* 2A variant, resulting in dihydropyrimidine dehydrogenase
deficiency, are at significantly increased risk of developing severe fluoropyrimidine …

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine,
are frequently prescribed for several types of cancer, including breast, colorectal, head and …

We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD)
variants to predict severe early‐onset fluoropyrimidine (FP) toxicity, in particular of a recently …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

PURPOSE DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of
DPYD variant alleles. However, the impact on treatment outcome in these patients is largely …

Background Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase
gene (DPYD) have a high risk to experience severe drug-adverse effects following …

Alterations in dihydropyrimidine dehydrogenase gene (DPYD) coding for the key enzyme
(DPD) of fluoropyrimidines (FPs) catabolism contribute to the development of serious FPs …